Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 674

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 674
---
� (TGF -ß) superfamily along with BMP -7. In nature, endogenous BMP7 promotes chondrogenesis in damaged cartilage tissue by signaling primarily via the type II receptor BMPRII and to a lesser extent via the activin type II receptor ActRII, which it binds with lower affinity. DRT -101amplifies intracellular regeneration signaling capacity compared to natural BMP -7and allows for regeneration and restoration of mechanically depleted cartilage cells to normal levels. Osteoarthritis is the most common joint disorder in the aging population. Although surgical treatment of osteoarthritis can reduce pain and improve joint mobility and function, the operative management of osteoarthritis is associated with significant cost and morbidity. Unmet medical needs for DRT -101for Osteoarthritis are enormous specially with aging population. Unique market opportunity of DRT -101relies on novel Mechanism of Action of DRT -101that can lead to potential first -in-classDMOAD (Disease -ModifyingOsteoarthritis Drug) in the market. Darnatein is pursuing pre -clinicalstudies of DRT -101targeting osteoarthritis and plans to file Investigational New Drug Application (IND) to the U.S. Food and Drug Administration by 2025 for Phase 1 clinical trial, with aims of FDA approval by 2032. Darnatein will seek to create cashflow via licensing deals from the preclinical and clinical developments of its pipeline assets.

F-134

33. Business combinations (cont.) Details of patent technology recognized from the acquisition of VAXIMM that occurred for the year ended December 31, 2022 are set forth in the table below.

| (Korean won in thousand)        |     |           Amount |
| Patent technology project code: |     |                  |
| VMX01-GBM (ROW and China)       |     | ₩     15,481,599 |
| VMX01-mCRC (ROW and China)      |     |       27,256,642 |
| VMX01-Liver (ROW and China)     |     |       41,927,472 |
| VMX01-NF2 (ROW and China)       |     |       16,214,016 |
| VXM-Preclinical                 |     |       29,047,708 |
| Total fair value                |     |   ₩  129